Molecure

We are pleased to announce another important milestone in the clinical development of 📣

has completed the dose-limiting toxicity (DLT) observation period in all patients treated with OATD-02 at the 40 mg QD dose level. Following review of the data collected so far, and with approval from the Safety Review Committee (SRC), the study has progressed to the 80 mg QD dose level.

Importantly, the data confirmed therapeutic target engagement - a key step toward identifying the pharmacologically active dose of our investigational arginase inhibitor. continues to advance in Phase 1 clinical development as a potential novel therapy in oncology! 🌍

We are pleased to announce that has been granted a US patent (US12612420 (B2)) for the latest series of arginase inhibitors! 📣

These inhibitors are backup compounds for , a frontrunner that is performing well in Phase 1 clinical trials (NCT05759923, https://clinicaltrials.gov/study/NCT05759923?term=oatd-02&viewType=Card&rank=1). This achievement underscores Molecure's global leadership in the field of arginase inhibitors 🌍

➡️Link to the patent: https://worldwide.espacenet.com/patent/search/family/079287969/publication/US12612420B2?q=pn%3DUS12612420B2

We are excited to share that our team members, Theodoros Charitos (Medical Director) and Katarzyna Drzewicka (Head of Early Discovery), are attending the International Conference in Orlando, FL (US) 🇺🇸

Our team, along with renowned co-authoring pulmonology and nuclear medicine clinicians, is showcasing the Phase 2 Study in pulmonary sarcoidosis and highlighting ’s ongoing work on . This abstract, in form of a poster, presents approaches to evaluating treatment response using advanced PET imaging methodologies. It is presented in the scientific session dedicated to biomarkers, imaging, and physiology in Interstitial Lung Diseases (ILDs) taking place today, May 20th, 2026. Its title is “Novel Semi-quantitative Fluorodeoxyglucose Positron Emission Tomography Response Criteria as Primary Endpoint in Pulmonary Sarcoidosis: Methodological Design and Implementation in the KITE Phase 2 Study” 🔬

Molecure team is proud to be part of the global scientific community efforts around innovative therapies for pulmonary diseases including ILDs/pulmonary sarcoidosis 🌍

, in collaboration with and , explores targeting ubiquitin-specific protease 7 ( ) 📖

is a deubiquitinating enzyme frequently overexpressed in cancer and linked to stabilization of oncogenic proteins and immunosuppressive factors. Structure-guided discovery and SAR-driven optimization efforts yielded selective USP7 inhibitors to explore this therapeutic target, with OAT-4828 emerging as a potent lead compound. The screening cascade, which led to the discovery of OAT-4828 incorporated cellular system, including primary T cells, where the compound increased T-cell killing capacity without causing toxicity – highlighting a scientifically new role of USP7 in immune cell activation. The pharmacokinetic profile in mice and preliminary safety assessments of OAT-4828 enabled in vivo studies. OAT-4828 was well-tolerated in mice, demonstrating significant antileukemic activity in a syngeneic model of B-cell derived non-Hodgkin lymphoma without systemic toxicity.

One of the key substrates regulated by USP7 is . With several MDM2 inhibitors currently in clinical development, the p53-MDM2 axis is firmly validated as a critical therapeutic target. Our latest research highlights how USP7 inhibition may offer a powerful, upstream approach to modulate this proven pathway.

Read more ➡️ https://pubs.acs.org/doi/10.1021/acs.jmedchem.6c00407